EGFR and metastatic colorectal cancer: Previously, Yaeger and colleagues (1) had performed a retrospective, multicenter study to characterize the response of non-BRAFV600E variants to a range of anti-EGFR treatment regimens, querying datasets from five centers for patients with metastatic colorectal cancer with non-BRAFV600E between 2010 and 2017.